The minimum protective dose of a tissue-culture-origin (TCO) modified laryngotracheitis (MLT) ocular vaccine was determined in 4-and 12-week-old White Rock broiler-type chickens. Vaccine seed stocks, prepared from different passage levels at widely differing points of time, were tested also. Data showed that the minimum protective dose for this vaccine is approximately 103.0 EID50/ml. Route of challenge (intratracheal vs. intrasinus), age of birds at vaccination, and housing conditions (cage vs. floor) had little effect on the outcome of these tests. Results of testing virus seed stocks confirmed the data obtained on commercial vaccine and also showed that the antigenic qualities of the virus are very stable.
INTRODUCTION
One of the common methods of expressing virus immunizing potential on a quantitative basis is the "minimum protective dose." As related to a vaccine, this is simply the minimum amount of virus which is capable of routinely immunizing a majority of the principals to be vaccinated. For convenience in relating to vaccine virus titers, this is usually expressed as virus concentration, either as EID50/ml or as TCID50/ml. Knowledge of the minimum protective dose and the virus titer of a vaccine allows one to predict the margin of efficacy at any given time during the life of the product.
Several published reports (4,5) have covered various aspects of the safety and immunologic characteristics of a tissue-cultureorigin (TCO) modified laryngotracheitis virus, first designated as atypical-lesion-forming (ALF) virus (4) and later as modified laryngotracheitis (MLT) vaccine (5). This virus was modified in chicken kidney and liver cell culture and was derived originally from the ASL L-6 virulent laryngotracheitis (LT) virus. Early reports dealt little with the aspect of minimum protective dose even though some work had been conducted on this during the original research on the virus. During the years since this was first investigated, additional tests have been performed to ascertain whether the virus had retained its basic immunizing potential while being manipulated as necessary to maintain seed stocks, etc. This report covers the latest of such tests, performed on the commonly called "LT-IVAX" virus.
MATERIALS AND METHODS
The vaccine used was regular production material lyophilized and stored at 5 C prior to use. Vaccine seed stocks, also tested, were stored at -70 C either lyophilized or frozen. Several diluents were used to reconstitute and dilute the virus for testing. These are specified in the text.
Virus dilutions tested in birds were titrated simultaneously for virus content using 10-day-old chicken embryos and the dropped-CAM technique of inoculation. Actual dilutions used in birds were inoculated into eggs. Lesions on the CAM were read 5 days postinoculation, and titer endpoints were determined by the method of Reed and Muench (6).
Vaccination was conducted by the eyedrop technique using commercial plastic dropper applicators delivering approximately 0.03 ml per bird. Separate applicators were used throughout for individual dilutions.
The chickens used were White Rock broiler-type reared in isolation from LT-susceptible parents. Hatchmate controls, held in isolation during the postvaccination period, were used routinely to demonstrate susceptibility of the test group and virulence of the challenge virus. Four-week-old birds were held in separated cage units kept in small colony houses. Experience has shown repeatedly that spread of this virus between groups is essentially nonexistent under these circumtances if watering facilities are separate. Spread within a cage group is known to be quite possible, however. Twelve-week-old birds were kept on the floor in separated colony houses.
Challenge was conducted 14 days postvaccination with 0.1 ml of the N71851 culture (3), titering 105.5 EID50/ml, administered either intrasinusly or intratracheally. In our laboratory, this stain has regularly produced typical LT signs in birds and is considered a virulent virus. Birds were examined 5 days postchallenge for sinus exudate or tracheal rales. When intratracheal challenge was used, observations were extended through 14 days postchallenge to determine mortality.
EXPERIMENTS AND RESULTS
Trial 1. Lyophilized vaccine, recently produced and known to have a virus titer of about 104.0 to 104.5 EID50/ml as diluted for field use, was reconstituted and diluted in half-log increments using sterile modified Hank's balanced salt solution (modified by addition of 0.5% lactalbumin hydrolysate). Virus titrations were conducted on the respective dilutions before and after use to vaccinate birds. Four-week-old chickens in groups of 10 were vaccinated as described earlier, and separate groups were challenged intrasinusly and intratracheally. Results are shown in Table 1 .
Trial 2. Vaccine material from the same production serial as that used in Trial 1 was reconstituted and diluted in half-log increments in sterile distilled water. (Other testing showed this virus to be most stable in distilled water. Therefore, the diluent was changed at this point.) Virus titrations were conducted only once, immediately before use of the vaccine dilutions, and only dilutions from 10-1.? to 10-3.0 were tested in birds. Twelve-week-old chickens in groups of 22 were vaccinated as previously described, and challenged intrasinusly. Results are shown in Table 2 .
Trial 3. Virus seed stocks, one lyophilized (L656) and one frozen (L001), were used for direct comparison of different-passage-level viruses propagated at widely differing points of time. Stock L656 was produced after initial plaque purification of the virus in tissue culture, whereas stock L001 was produced 4 years later and represented seed material 4 passages removed from L656. 
Characteristics of a vaccine for infectious laryngotracheitis
The stocks were reconstituted and diluted in half-log increments in sterile distilled water. Virus titrations were conducted on the respective dilutions before and after use to vaccinate birds. Fourweek-old chickens in groups of 10 were vaccinated as previously described, and challenged intrasinusly. Results are shown in Table  3 .
DISCUSSION
Precise determination of the exact minimum-protective-dose endpoint for a virus such as the one tested herein is difficult for several reasons. Firstly, inherent variations in the chicken-embryo virus-assay technique make it impossible to determine virus content exactly. This might have been avoided somewhat by using cell-culture plaque-counting techniques which are generally regarded as being more accurate. However, because of its simplicity, the embryo titration system has been used routinely for years as the quality control test for determining virus content of this vaccine. Since it was desirable to relate this work as closely as possible to that conducted in quality control testing, it was decided to use the chicken embryo technique. Secondly, spread of the vaccine virus, which is known to be possible between birds within a cagegroup, makes it impossible to know which birds were protected as a result of initial vaccine application and which might have been protected as a result of virus spread during the postvaccination period. This problem could have been avoided by using singlebird isolation units, but one might then question the practical significance of the data obtained. In our opinion, the data reported here have significant value as an aid in predicting vaccine efficacy and in expressing virus immunizing potential.
Data from Trials 1 and 2 (Tables 1, 2) show that TCO MLT vaccine containing about 102.5 to 103-0 EID5o/ml was capable of protecting 80 to 90% of birds vaccinated ocularly, whereas vaccine containing 103-0 to 103-5 EID50/ml protected essentially 100%. These data are further substantiated by the results of Trial 3 (Table 3) showing that virus stock material titering as low as 102.0 to 102.5 EID5o/ml protected about 80% of the vaccinates, and material titering 1025 to 1030 There is little additional published data on this subject. Churchill (2) reported on an ocular LT vaccine prepared from a naturally occurring mild strain of virus grown in chicken embryos. His data showed that vaccine containing 300 PFU/0.03 ml (approximately 104-0 EID5o/ml) was capable of protecting 90% of adult chickens challenged intratracheally. No definite endpoint of protection was reached, however.
Route of challenge apparently has little effect on the outcome of minimum-protective-dose experiments. Table 1 indicates no significant difference between intrasinus and intratracheal challenge insofar as susceptibility is concerned. However, intratracheal challenge was more severe with regard to outcome for the bird. Numerous deaths were encountered by this route. This is commensurate with past experience showing that intratracheal challenge, especially aerosol exposure, is the most sensitive route for determining virulence of LT viruses.
Age of birds at vaccination and housing also appeared to have little effect on the minimum protective dose. Results were very similar in Trial 1 (Table 1 ) with 4-week-old birds kept in cages and Trial 2 ( Table 2 ) with 12-week-old birds kept on the floor in colony houses.
Comparative tests on different-passage-level seed stocks (Table 3 ) prepared at different times and held under different conditions showed no significant changes in the basic immunizing potential of the virus strain. The minimum-protective-dose value for this virus is apparently very stable, and antigenic variation in viral progeny is minimal. This contributes greatly to production of a uniform vaccine of consistent immunizing value.
